Onko Solutions, LLC is a company committed to the development and commercialization of innovative technology solutions that contribute to the detection, prevention and treatment of cancer in underserved populations.
We are dedicated to transforming lives with reliable solutions in the detection and treatment of cancer that offer immediate results and are affordable for everyone.
We are currently working in early cervical cancer detection. Mortality related to cervical cancer is rare among women who get screened regularly. However, only 40 to 50% of women in developed countries get screened every year, while in underdeveloped countries that number drops to an alarming 5%.
There is an urgent need for palpable, cost-effective, reproducible and non-invasive solutions that significantly reduce the fatalities attributed to cervical cancer. Such solutions are especially urgent in developing countries that lack the resources and equipment to perform cytodiagnosis.
Onko Solutions has developed a portable medical device for effective, reliable, fast and non-invasive screening for cervical cancer that unlike Pap smears, HPV tests, or biopsies, does not require laboratory analysis or a tissue sample, making it ideal and available to underprivileged regions.
Our device is designed to provide non-invasive screening with instantaneous results, eliminating costly, painful and unnecessary lab work.
Verbal Commitment from 2 institutional investors for another $650,000 USD investment pending a trial of 150 women in Guadalajara, MX.July, 2015
Regulatory approval (TruScreen by Onko Solutions)July, 2015
Sales begin in Mexico (TruScreen by Onko Solutions)August, 2015
Complete product development of proprietary solutionNovember, 2015
Complete clinical trials of proprietary solutionDecember, 2015
Proprietary product receives approval to be marketed in MexicoFebruary, 2016
Sales begin in MexicoApril, 2016
Sales begin in Latin AmericaJune, 2016
Technology feasibility testing for FDA approvalMay, 2016
Present pre-submission package for FDA approvalAugust, 2016
Initiate clinical trials FDA/CE MarkOctober, 2016